WARREN, N.J., Feb. 9, 2015 (GLOBE NEWSWIRE) -- MonoSol Rx, the developer of PharmFilm® drug delivery technology, presented the Company's technology recently at the International Association for Pharmaceutical Technology (IAPT) in Innsbruck, Austria. MonoSol Rx Chief Innovation & Technology Officer A. Mark Schobel was a lead presenter at the ODx and MBx - Orodispersible and Mucoadhesive Buccal Formulations seminar hosted by the IAPT. His session, titled, "Mucoadhesive Buccal Films" (MBFs), highlighted MonoSol's PharmFilm delivery technology, product development strategy and pipeline including the MSRX-301 transbuccal oral insulin film currently moving toward Phase II clinical trials.
"The IAPT is a leading organization committed to the development of innovative pharmaceutical technologies. I was honored to present our game-changing technology to an audience of thought leaders in pharmaceutical product and business development, manufacturing and regulatory affairs at this prestigious seminar," Schobel said. "This conference is one of the largest dedicated exclusively to orodispersible and mucoadhesive buccal formulations in drug development and drew a significant crowd from throughout the global pharma industry. The large participation reflected the growing market interest in oral film-based drug product technologies as an optimal delivery approach for a number of compounds to treat an expanding range of indications."
The IAPT is a nonprofit scientific society committed to furthering scientific research for the development, manufacture, distribution and use of medical products. The organization's ODx and MBx seminar will focus on recent innovations in formulation development, manufacturing and quality control, biopharmaceutical methods for characterization and regulatory issues.
MonoSol Rx currently has two commercialized oral film products: Suboxone® (Buprenorphine/Naloxone) for the treatment of opioid dependence and Zuplenz® (Ondansetron) for treatment of nausea and vomiting in patients receiving chemotherapy. In addition, the Company's pipeline includes a transbuccal oral insulin film product for blood glucose management in diabetics and an oral film for testosterone replacement to treat hypogonadism, both of which are currently in Phase II trials. The Company has four additional complex molecule product candidates currently in various stages of preclinical development.
More information about the ODx and MBx - Orodispersible and Mucoadhesive Buccal Formulations seminar can be found at http://www.apv-mainz.de/. For more information about MonoSol Rx, visit http://www.monosolrx.com.
About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to develop products which address the unmet needs of patients. PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company's leadership in film drug delivery is supported by strong intellectual property, a pipeline of prescription formulations based on PharmFilm® technology, and two FDA approvals — Zuplenz®, the first approved prescription oral soluble film for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting, and Suboxone® sublingual film, the first sublingual film product for the treatment of opioid dependence. For press releases and other company information visit www.monosolrx.com.
About The Association for Pharmaceutical Technology
The Association for Pharmaceutical Technology (APV) is a nonprofit scientific society. Its main objective is to deepen the scientific evidence on the development, manufacture, distribution and use of medicinal products and to communicate this knowledge.
CONTACT: MonoSol Rx: Sanford Plachter Marketing Manager (732) 564-5000 The Ruth Group Investor Relations Lee Roth (646) 536-7012 email@example.com Media Relations Melanie Sollid-Penton (646) 536-7023 firstname.lastname@example.orgSource: MonoSol Rx